Literature DB >> 15469189

Spatial and temporal parameters of gait disturbances in schizophrenic patients.

Albert Putzhammer1, Bernhard Heindl, Karin Broll, Liane Pfeiff, Maria Perfahl, Göran Hajak.   

Abstract

This study assessed the locomotor patterns of gait in schizophrenic patients and differentiated intrinsic effects of the illness from those caused by conventional and atypical neuroleptic treatment. Gait parameters of drug-naïve, conventionally and atypically treated patients as well as control subjects were evaluated. Differences in gait velocity and in stride length between the four investigated groups were highly significant (ANOVA: p<0.001). Mean gait velocities of all patient groups were significantly slower than those of controls, with the most striking difference observed between the control group and patients treated with conventional neuroleptics (p <0.001). Amongst the patient groups, significant differences were detected between patients treated with conventional neuroleptics and both patients treated with atypical neuroleptics and drug-naïve patients (p < 0.05), but not between untreated and atypically treated patients. In all patient groups the reduction of gait velocity was due to a smaller mean stride length, while the cadence (steps per minute) was not changed. These results indicate that schizophrenia causes a primary disturbance of stride length regulation. Conventional antipsychotic treatment intensifies this deficit, whereas atypical antipsychotic treatment does not cause any additional gait disturbances. In contrast to the spatial parameters, the temporal structure of schizophrenic gait is not affected either by antipsychotic treatment or schizophrenia itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469189     DOI: 10.1016/s0920-9964(03)00090-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Gait and its assessment in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2010-07

Review 2.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

3.  Gait control and executive dysfunction in early schizophrenia.

Authors:  Elise Lallart; Roland Jouvent; François R Herrmann; Fernando Perez-Diaz; Xavier Lallart; Olivier Beauchet; Gilles Allali
Journal:  J Neural Transm (Vienna)       Date:  2013-11-08       Impact factor: 3.575

4.  Motor function deficits in schizophrenia: an fMRI and VBM study.

Authors:  Sadhana Singh; Satnam Goyal; Shilpi Modi; Pawan Kumar; Namita Singh; Triptish Bhatia; Smita N Deshpande; Subash Khushu
Journal:  Neuroradiology       Date:  2014-02-23       Impact factor: 2.804

5.  Upper body 3-dimensional kinematics during gait in psychotic patients: a pilot-study.

Authors:  A Stensdotter; N Pedersen; A Wanvik; F Öhberg; J C Fløvig; E A Fors
Journal:  Exp Brain Res       Date:  2012-07-22       Impact factor: 1.972

6.  Psychomotor Slowing in Schizophrenia: Implications for Endophenotype and Biomarker Development.

Authors:  K Juston Osborne; Sebastian Walther; Stewart A Shankman; Vijay A Mittal
Journal:  Biomark Neuropsychiatry       Date:  2020-05-12

7.  Therapeutic effects of maximal strength training on walking efficiency in patients with schizophrenia - a pilot study.

Authors:  Jørn Heggelund; Gunnar Morken; Jan Helgerud; Geir E Nilsberg; Jan Hoff
Journal:  BMC Res Notes       Date:  2012-07-03

Review 8.  Quantitative analysis of motor disturbances in schizophrenic patients.

Authors:  Albert Putzhammer; Helmfried E Klein
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

9.  Effects of virtual reality exercise for Korean adults with schizophrenia in a closed ward.

Authors:  Garam Jo; Brenda Rossow-Kimball; Gwitaek Park; Yongho Lee
Journal:  J Exerc Rehabil       Date:  2018-02-26

10.  Posture and gait in the early course of schizophrenia.

Authors:  Valentina Presta; Francesca Paraboschi; Filippo Marsella; Valeria Lucarini; Daniela Galli; Prisco Mirandola; Antonio Banchini; Carlo Marchesi; Laura Galuppo; Marco Vitale; Matteo Tonna; Giuliana Gobbi
Journal:  PLoS One       Date:  2021-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.